Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.

Sang Youb HanSun Ae YoonByoung Geun HanSung Gyun KimYoung-Il JoKyung Hwan JeongKook-Hwan OhHyeong Cheon ParkSun-Hee ParkShin-Wook KangKi-Ryang NaSun Woo KangNam-Ho KimYounghwan JangBogyeong KimSeonghye ShinDae Ryong Cha

Published in: Diabetes, obesity & metabolism (2017)

Gemigliptin and linagliptin did not differ with respect to safety and efficacy in patients with T2DM and renal impairment. The 2 drugs had similar glucose-lowering effects, and the changes in eGFR and albuminuria were also similar. Additionally, the risk of side effects, including hypoglycaemia, was similar between the 2 groups.

Keyphrases

type diabetes
glycemic control
small cell lung cancer
cardiovascular disease
blood glucose
randomized controlled trial
clinical trial
metabolic syndrome
blood pressure
skeletal muscle
drug induced